Aldevron

Aldevron is a privately-held, revenue-generating CDMO that serves as a foundational supplier to the biotechnology sector, particularly in the fast-growing fields of gene therapy, cell therapy, gene editing, and RNA therapeutics. The company operates a diversified business model offering both standardized catalog products and comprehensive custom manufacturing services, supported by multiple GMP-certified facilities. A key strategic partnership with Integrated DNA Technologies (IDT) and recent expansion into lipid nanoparticle (LNP) encapsulation and fill/finish capabilities position Aldevron as an integrated solutions provider for next-generation medicines. Its successful role in manufacturing the world's first mRNA-based personalized CRISPR therapy underscores its technical proficiency and central role in advancing cutting-edge treatments.

Integrated CDMO platform for genomic medicine, specializing in plasmid DNA (traditional & Nanoplasmid), mRNA (including LNP encapsulation & fill/finish), protein/enzyme production (e.g., CRISPR nucleases), and viral vector plasmid systems.

Aldevron competes in a crowded but growing CDMO market for advanced therapies. Key competitors include large, established players like Lonza, Catalent, and Charles River Laboratories, as well as specialized firms like Thermo Fisher Scientific (Patheon), Oxford Biomedica, and Genezen. Its differentiation lies in its deep specialization in plasmid DNA and enzymes, its integrated mRNA service offering, and the strategic backing and cross-selling potential from being part of the Danaher ecosystem.